REFERENCES
2. Farmakis D, Porter J, Taher A, Domenica Cappellini M, Angastiniotis M, Eleftheriou A. 2021 thalassaemia international federation guidelines for the management of transfusion-dependent thalassemia. Hemasphere. 2022;6:e732.
3. Hentze MW, Muckenthaler MU, Andrews NC. Balancing acts: molecular control of mammalian iron metabolism. Cell. 2004;117:285-97.
5. Shah FT, Sayani F, Trompeter S, Drasar E, Piga A. Challenges of blood transfusions in β-thalassemia. Blood Rev. 2019;37:100588.
6. Modell B, Khan M, Darlison M, Westwood MA, Ingram D, Pennell DJ. Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2008;10:42.
7. Pepe A, Pistoia L, Gamberini MR, et al. National networking in rare diseases and reduction of cardiac burden in thalassemia major. Eur Heart J. 2022;43:2482-92.
8. Anderson LJ, Holden S, Davis B, et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J. 2001;22:2171-9.
10. Kirk P, Roughton M, Porter JB, et al. Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation. 2009;120:1961-8.
11. Pepe A, Meloni A, Rossi G, et al. Prediction of cardiac complications for thalassemia major in the widespread cardiac magnetic resonance era: a prospective multicentre study by a multi-parametric approach. Eur Heart J Cardiovasc Imaging. 2018;19:299-309.
12. Berdoukas V, Chouliaras G, Moraitis P, Zannikos K, Berdoussi E, Ladis V. The efficacy of iron chelator regimes in reducing cardiac and hepatic iron in patients with thalassaemia major: a clinical observational study. J Cardiovasc Magn Reson. 2009;11:20.
13. Pennell DJ, Porter JB, Cappellini MD, et al. Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major. Haematologica. 2012;97:842-8.
14. Pepe A, Meloni A, Pistoia L, et al. MRI multicentre prospective survey in thalassaemia major patients treated with deferasirox versus deferiprone and desferrioxamine. Br J Haematol. 2018;183:783-95.
15. Pepe A, Meloni A, Rossi G, et al. Cardiac complications and diabetes in thalassaemia major: a large historical multicentre study. Br J Haematol. 2013;163:520-7.
16. Albakri A. Iron overload cardiomyopathy: a review of literature on clinical status and meta-analysis of diagnostic and clinical management using iron chelators. Int Med Care. 2018:2.
17. Kremastinos DT, Tiniakos G, Theodorakis GN, Katritsis DG, Toutouzas PK. Myocarditis in beta-thalassemia major. A cause of heart failure. Circulation. 1995;91:66-71.
18. Pepe A, Positano V, Capra M, et al. Myocardial scarring by delayed enhancement cardiovascular magnetic resonance in thalassaemia major. Heart. 2009;95:1688-93.
19. Wood JC. Cardiac complications in thalassemia throughout the lifespan: victories and challenges. Ann N Y Acad Sci. 2023;1530:64-73.
20. Dahiya A, Vollbon W, Jellis C, Prior D, Wahi S, Marwick T. Echocardiographic assessment of raised pulmonary vascular resistance: application to diagnosis and follow-up of pulmonary hypertension. Heart. 2010;96:2005-9.
21. Cho IJ, Mun YC, Kwon KH, Shin GJ. Effect of anemia correction on left ventricular structure and filling pressure in anemic patients without overt heart disease. Korean J Intern Med. 2014;29:445-53.
22. Hegde N, Rich MW, Gayomali C. The cardiomyopathy of iron deficiency. Tex Heart Inst J. 2006;33:340-4.
23. Bellenger NG, Burgess MI, Ray SG, et al. Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance; are they interchangeable? Eur Heart J. 2000;21:1387-96.
24. Puntmann VO, Valbuena S, Hinojar R, et al; SCMR Clinical Trial Writing Group. Society for Cardiovascular Magnetic Resonance (SCMR) expert consensus for CMR imaging endpoints in clinical research: part I - analytical validation and clinical qualification. J Cardiovasc Magn Reson. 2018;20:67.
25. Ibrahim EH, Frank L, Baruah D, et al. Value CMR: towards a comprehensive, rapid, cost-effective cardiovascular magnetic resonance imaging. Int J Biomed Imaging. 2021;2021:8851958.
26. Meloni A, Pistoia L, Gamberini MR, et al. Multi-parametric cardiac magnetic resonance for prediction of heart failure death in thalassemia major. Diagnostics. 2023;13:890.
27. Aimo A, Teis A, Kasa G, et al. Left-to-right ventricular volume ratio and outcome in heart failure with preserved ejection fraction. J Cardiovasc Med. 2023;24:552-60.
28. Altmayer SP, Patel AR, Addetia K, Gomberg-Maitland M, Forfia PR, Han Y. Cardiac MRI right ventricle / left ventricle (RV/LV) volume ratio improves detection of RV enlargement. J Magn Reson Imaging. 2016;43:1379-85.
29. McCracken C, Szabo L, Abdulelah ZA, et al. Ventricular volume asymmetry as a novel imaging biomarker for disease discrimination and outcome prediction. Eur Heart J Open. 2024;4:oeae059.
30. Moccia E, Papatheodorou E, Miles CJ, et al. Arrhythmogenic cardiomyopathy and differential diagnosis with physiological right ventricular remodelling in athletes using cardiovascular magnetic resonance. Int J Cardiovasc Imaging. 2022;38:2723-32.
31. Luijkx T, Velthuis BK, Prakken NH, et al. Impact of revised task force criteria: distinguishing the athlete’s heart from ARVC/D using cardiac magnetic resonance imaging. Eur J Prev Cardiol. 2012;19:885-91.
32. Meloni A, Ramazzotti A, Positano V, et al. Evaluation of a web-based network for reproducible T2* MRI assessment of iron overload in thalassemia. Int J Med Inform. 2009;78:503-12.
33. Ramazzotti A, Pepe A, Positano V, et al. Multicenter validation of the magnetic resonance T2* technique for segmental and global quantification of myocardial iron. J Magn Reson Imaging. 2009;30:62-8.
34. Meloni A, Righi R, Missere M, et al. Biventricular reference values by body surface area, age, and gender in a large cohort of well-treated thalassemia major patients without heart damage using a multiparametric CMR approach. J Magn Reson Imaging. 2021;53:61-70.
35. Marsella M, Borgna-Pignatti C, Meloni A, et al. Cardiac iron and cardiac disease in males and females with transfusion-dependent thalassemia major: a T2* magnetic resonance imaging study. Haematologica. 2011;96:515-20.
36. Meloni A, Restaino G, Borsellino Z, et al. Different patterns of myocardial iron distribution by whole-heart T2* magnetic resonance as risk markers for heart complications in thalassemia major. Int J Cardiol. 2014;177:1012-9.
37. Meloni A, Luciani A, Positano V, et al. Single region of interest versus multislice T2* MRI approach for the quantification of hepatic iron overload. J Magn Reson Imaging. 2011;33:348-55.
38. Cerqueira MD, Weissman NJ, Dilsizian V, et al; American Heart Association Writing Group on Myocardial Segmentation and Registration for Cardiac Imaging. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: a statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation. 2002;105:539-42.
39. Wood JC, Enriquez C, Ghugre N, et al. MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood. 2005;106:1460-5.
40. Meloni A, Rienhoff HY Jr, Jones A, Pepe A, Lombardi M, Wood JC. The use of appropriate calibration curves corrects for systematic differences in liver R2* values measured using different software packages. Br J Haematol. 2013;161:888-91.
41. Angelucci E, Brittenham GM, McLaren CE, et al. Hepatic iron concentration and total body iron stores in thalassemia major. N Engl J Med. 2000;343:327-31.
42. McDonagh TA, Metra M, Adamo M, et al; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2021;42:3599-726.
43. Buxton AE, Calkins H, Callans DJ, et al; American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (ACC/AHA/HRS Writing Committee to Develop Data Standards on Electrophysiology). ACC/AHA/HRS 2006 key data elements and definitions for electrophysiological studies and procedures: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (ACC/AHA/HRS Writing Committee to Develop Data Standards on Electrophysiology). Circulation. 2006;114:2534-70.
44. Cogliandro T, Derchi G, Mancuso L, et al; Society for the Study of Thalassemia and Hemoglobinopathies (SoSTE). Guideline recommendations for heart complications in thalassemia major. J Cardiovasc Med. 2008;9:515-25.
45. Sayed SZ, Aly BA, Abd El-hakim AEA, M Omar S, Amin AS. The early cardiac involvement in patients with β-thalassemia major. The Egyptian Heart Journal. 2013;65:243-9.
46. Akiki N, Hodroj MH, Bou-fakhredin R, Matli K, Taher AT. Cardiovascular complications in β-Thalassemia: getting to the heart of it. Thalassemia Reports. 2023;13:38-50.
47. Patel N, Gonsalves CS, Malik P, Kalra VK. Placenta growth factor augments endothelin-1 and endothelin-B receptor expression via hypoxia-inducible factor-1α. Blood. 2008;112:856-65.
48. Meloni A, Detterich J, Pepe A, Harmatz P, Coates TD, Wood JC. Pulmonary hypertension in well-transfused thalassemia major patients. Blood Cells Mol Dis. 2015;54:189-94.
49. d’Humières T, Sadraoui Z, Savale L, et al. Atrial arrhythmia in adults with sickle cell anemia: a missing link toward understanding and preventing strokes. Blood Adv. 2024;8:5625-38.
50. Gorter TM, van Melle JP, Rienstra M, et al. Right heart dysfunction in heart failure with preserved ejection fraction: the impact of atrial fibrillation. J Card Fail. 2018;24:177-85.
51. Meloni A, Pistoia L, Quota A, et al. Prognostic value of multiparametric cardiac magnetic resonance in sickle cell patients. Ann Hematol. 2023;102:261-70.
52. Altmayer SPL, Han QJ, Addetia K, Patel AR, Forfia PR, Han Y. Using all-cause mortality to define severe RV dilation with RV/LV volume ratio. Sci Rep. 2018;8:7200.
53. Bax S, Jacob J, Ahmed R, et al. Right ventricular to left ventricular ratio at CT pulmonary angiogram predicts mortality in interstitial lung disease. Chest. 2020;157:89-98.
54. Becattini C, Agnelli G, Germini F, Vedovati MC. Computed tomography to assess risk of death in acute pulmonary embolism: a meta-analysis. Eur Respir J. 2014;43:1678-90.
55. Naeije R, Badagliacca R. The overloaded right heart and ventricular interdependence. Cardiovasc Res. 2017;113:1474-85.
56. Kerber RE, Dippel WF, Abboud FM. Abnormal motion of the interventricular septum in right ventricular volume overload: experimental and clinical echocardiographic studies. Circulation. 1973;48:86-96.
57. Arcari L, Ciavarella GM, Altieri S, et al. Longitudinal changes of left and right cardiac structure and function in patients with end-stage renal disease on replacement therapy. Eur J Intern Med. 2020;78:95-100.
58. Izzy M, VanWagner LB, Lin G, et al; Cirrhotic Cardiomyopathy Consortium. Redefining cirrhotic cardiomyopathy for the modern era. Hepatology. 2020;71:334-45.
59. Jahangir E, Harinstein ME, Murthy VL, Moslehi J. The forgotten right ventricle in cardio-oncology. J Nucl Cardiol. 2020;27:2164-6.
60. Pena E, Brito J, El Alam S, Siques P. Oxidative stress, kinase activity and inflammatory implications in right ventricular hypertrophy and heart failure under hypobaric hypoxia. Int J Mol Sci. 2020;21:6421.
